Abstract
Abstract Background: The purpose of this study was to determine the prevalence of metabolic syndrome (MetS) and its components in cancer survivors (CS) compared to participants without a history of cancer who have at least one chronic disease (CD) and those without a chronic disease diagnosis (NCD). Methods: Using National Health and Nutrition Examination Survey (NHANES) data from 2015 to 2018, the prevalence MetS was evaluated among participants 50 years and older (n= 5466). MetS was defined based on the National Cholesterol Education Program’s Adult Treatment Panel III. Weighted data were used to estimate the prevalence of MetS, stratified by cancer site, gender, sex, and race/ethnicity. Chi-square test and logistic regression was used to assess group comparisons and associations respectively. Results: Prevalence of MetS was higher among CS (71.4%) and CD (75.1%) participants compared to NCD (45.7%). Compared to NCD, participants with uterine cancer (UCa) and non-melanoma skin cancer (nMSC) had higher odds of MetS, with and without adjusting for covariates (p<0.05). Those with UCa had the highest odds of MetS (OR 3.49, CI 1.51 - 8.06, p<0.01) among all cancer types and NCD respondents. Regarding individual components of MetS, PCa survivors had lower odds of having elevated WC (p<0.01) and BrCa and UCa had higher odds of having elevated WC (p<0.05) after adjusting for covariates, compared to NCD. nMSC had higher odds of reduced HDL, elevated TG, and elevated WC (p<0.05) after adjusting for covariates. Conclusions: This study indicates that UCa and nMSC survivors have a strong association with MetS. In particular, nMSC survivors demonstrated statistically significant odds of meeting 3 of the 5 risk factors for MetS after adjusting for confounding variables. A better understanding of the association between MetS, its components, and specific cancers can provide insight into providing complete clinical care to CS. Citation Format: Adaora Ezeani, Tanya Agurs-Collins. Prevalence of metabolic syndrome among cancer survivors in the US [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB157.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
